drugset / Trial / NCT00696631

European Trial of Dronedarone in Moderate to Severe Congestive Heart Failure

NCT00696631

Phase 3 Terminated 653 enrolled Sanofi
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess the efficacy, tolerability and safety of dronedarone versus placebo in patients with symptomatic congestive heart failure (CHF) and left ventricular dysfunction (LVD) when added to evidence based treatments for CHF.

Timeline

Start
2002-06
Primary completion
2003-01
Completion
2003-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Dronedarone Small molecule 400 mg